According to Cowen analyst Phil Nadeau, third party sources indicated that Gilead Sciences, Inc. (NASDAQ:GILD) increased today the U.
In a research report published Friday, Cowen analyst Phil Nadeau reiterated an Outperform rating on shares of Acorda Therapeutics Inc (NASDAQ:ACOR), while reducing the price …
On Sep 21, Gilead Sciences, Inc. (NASDAQ:GILD) announced data from four of its Phase 3 studies: ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-4, for the …
Cowen’s healthcare analyst Phil Nadeau weighed in today with a few insights on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), following Monday’s news that the company’s exploratory Phase 2a …
Cowen’s healthcare analyst Phil Nadeau came out with some commentary on Sarepta Therapeutics Inc (NASDAQ:SRPT), after the company released its second-quarter results and provided update on its …
In a research report released today, Cowen analyst Phil Nadeau downgraded shares of XOMA Corp (NASDAQ:XOMA) from an Outperform to a Market Perform rating, …
Second quarter earnings season is upon us and Cowen & Co. is counting on the biotechnology sector to deliver.
Cowen analyst Phil Nadeau weighed in today with a few insights on XOMA Corp (NASDAQ:XOMA), as data from gevokizumab’s EYEGUARD-B trial is expected over the next couple of weeks. This program …
Cowen analyst Phil Nadeau weighed in today with a few observations on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), following the company’s announcement that it has partnered its …
Cowen’s healthcare analyst Phil Nadeau weighed in today with a favorable report on Gilead Sciences, Inc. (NASDAQ:GILD), following the release of Gilead’s first-quarter earnings report, showing HCV revenue …
